Business Wire
http://www.incyte.com
August 23, 2012 04:10 PM Eastern Daylight Time 

Incyte to Present at Upcoming Investor Conferences

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq:INCY) announced today it will present at the following investor conferences during the month of September:

  • Robert W. Baird & Co. 2012 Health Care Conference on Wednesday, September 5, 2012 at 10:10 a.m. (ET) in New York City;
  • Morgan Stanley Global Healthcare Conference on Wednesday, September 12, 2012 at 10:55 a.m. (ET) in New York City;
  • ThinkEquity’s 9th Annual Growth Conference on Thursday, September 13, 2012 at 1:30 p.m. (ET) in New York City; and
  • UBS Global Life Sciences Conference on Thursday, September 20, 2012 at 1:00 p.m. (ET) in New York City

The presentations will be webcast live and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts. A replay of the presentations will be available. Investors interested in listening to the live webcast should log on before the start time in order to download any software required.

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs for oncology and inflammation. For additional information on Incyte, please visit the Company's web site at www.incyte.com.

Contacts

Incyte Corporation
Pamela M. Murphy
Vice President, Investor Relations/Corporate Communications
302-498-6944

Recent Stories

  • View Press Release
    Incyte Drug Jakafi® (ruxolitinib) Improved Overall Survival in Phase III Trial of Patients with Myelofibrosis
    June 16, 2013
    STOCKHOLM--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) today announced results from two ongoing clinical trials of Jakafi® (ruxolitinib), an oral JAK1 and JAK2 inhibitor that is FDA-approved... more »
  • View Press Release
    Jakafi® (ruxolitinib) Prescribing Information Updated with Expanded Dosing Guidance and New Safety Information
    June 12, 2013
    WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) announced today that the U.S. Food and Drug Administration (FDA) has updated prescribing information for Jakafi® (ruxolitinib) t... more »
  • View Press Release
    Data Presented at 2013 ASCO Offers First Evidence that Long-Term Treatment with Jakafi® (ruxolitinib) May Stabilize or Reverse Bone Marrow Fibrosis, a Key Marker of Worsening Disease in Patients with Myelofibrosis
    June 04, 2013
    CHICAGO--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) announced that results from an exploratory analysis of bone marrow fibrosis data from an ongoing Phase I/II single-arm, open-label clinic... more »
More Stories
RSS feed for Incyte Corporation
http://www.incyte.com

Release Versions

  • EON: Enhanced Online News

Company Information Center

Incyte Corporation RSS feed for Incyte Corporation

NASDAQ:INCY

Share

  • Facebook
  • Twitter
  • LinkedIn
  • Delicious
  • Reddit
  • StumbleUpon
  • Digg
  • MySpace
  • Newsvine
  • Google Bookmark
  • Yahoo! Bookmark
  • EmailEmail
Tweet
  • EmailEmail
All News
Business Wire

Site Navigation

  • Home
    • Home
    • Submit a Press Release
  • Services
    • Overview
    • Targeting
    • Distribution
    • Financial Disclosure
    • Measurement & Analytics
    • Event News Services
    • Media & Journalist Tools
  • News
    • All News
    • News with Multimedia
    • News by Industry
    • News by Subject
    • News by Language
    • Tradeshows & Events
    • Earnings & Conference Calls
  • Education
    • Overview
    • Sample Press Release
    • FAQ
    • Find Your News Online
    • How-to
    • Disclosure Resources
    • White Papers
  • About Us
    • Overview
    • Become a Member
    • Contact Us
    • Follow Us
    • Jobs
    • Business Wire Newsroom

Search

Advanced News Search
  • Log In
  • Sign Up

Follow Us

  • Twitter
  • LinkedIn

More from Business Wire

  • Blog
  • Apps
  • Canada
  • UK/Ireland
  • Deutschland
  • France
  • Italy
  • Japan
  • EON: Enhanced Online News
  • Tradeshownews.com
  • PYMNTS.com

Business Wire Information

  • Contact Us
  • Privacy Statement
  • Terms of Use
  • ©2013 Business Wire